Overview

Reappraisal of GIK in Acute STEMI by Pre-hospital Administration

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is: 1. to assess whether pre-hospital glucose-insulin-potassium (GIK) administration in acute STEMI patients would reduce infarct size and ischemia/reperfusion damage using comprehensive tissue characterization by cardiovascular magnetic resonance (CMR) at an early post-infarction phase. 2. to explore the putative cardioprotective mechanisms of pre-hospital GIK administration
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Centre Hospitalier Universitaire Vaudois
Treatments:
Insulin
Insulin, Globin Zinc
Criteria
Inclusion Criteria:

1. Patients with the diagnosis of acute STEMI

2. ageā‰„ 18

3. informed consent for study participation.

Exclusion Criteria evaluated during ambulance transport to primary PCI center:

1. end-stage renal failure requiring dialysis,

2. prior MI or coronary revascularization (PCI or CABG),

3. active malignances,

4. Pregnancy,

5. Hemodynamic instability (systolic blood pressure <100mmHg or significant pulmonary
congestion defined as O2 saturation <90% on ambient air at pulso-oxymetry)

Exclusion Criteria evaluated after hospital admission at the primary PCI center (all
patients will be re-evaluated for study continuation):

1. total ischemic time more than 8 hours (from symptoms onset to infarct-related artery
mechanical re-opening)

2. evidence at diagnostic angiograms of TIMI flow-grade >1 of infarct-related artery or
significant epicardial collaterals to the ischemic myocardium at risk (Rentrop
flow-grade >1),

3. moderate-to-severe renal failure (estimated glomerular filtration rate < 30
ml/min/1.73 m2 by Cockcroft-Gault formula) and

4. urgent CABG.